Katie Peng - Aug 21, 2024 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Role: Director
Signature: /s/ Nick Harvey, Attorney-in-Fact
Stock symbol: ACET
Transactions as of: Aug 21, 2024
Transactions value $: $0
Form type: 4
Date filed: 8/23/2024, 04:07 PM
Previous filing: Jul 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACET	Stock Option (Right to Buy)	Disposed to Issuer	$0	-70.2K	-100%	$0.00	0	Aug 21, 2024	Common Stock	70.2K	$2.14	Direct	F1, F2
transaction	ACET	Stock Option (Right to Buy)	Award	$0	+70.2K		$0.00	70.2K	Aug 21, 2024	Common Stock	70.2K	$3.38	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2	The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on July 10, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

Content

Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on July 10, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.